Fate Therapeutics Inc (FATE) Given New $7.00 Price Target at BMO Capital Markets

Fate Therapeutics Inc (NASDAQ:FATE) had its target price upped by BMO Capital Markets to $7.00 in a research report sent to investors on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

FATE has been the subject of several other research reports. Zacks Investment Research cut Fate Therapeutics from a buy rating to a hold rating in a report on Tuesday, March 7th. Wedbush restated an outperform rating and issued a $7.00 price target on shares of Fate Therapeutics in a report on Tuesday, February 28th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $5.88.

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics (NASDAQ:FATE) traded up 8.84% during mid-day trading on Friday, hitting $5.05. 1,460,397 shares of the company were exchanged. Fate Therapeutics has a 12 month low of $1.47 and a 12 month high of $5.68. The firm has a 50 day moving average price of $3.75 and a 200 day moving average price of $3.01. The stock’s market cap is $172.45 million.

Your IP Address:

Institutional investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. raised its position in Fate Therapeutics by 14.1% in the fourth quarter. Franklin Resources Inc. now owns 6,076,879 shares of the biopharmaceutical company’s stock valued at $15,084,000 after buying an additional 751,879 shares in the last quarter. Renaissance Technologies LLC raised its position in Fate Therapeutics by 11.6% in the fourth quarter. Renaissance Technologies LLC now owns 209,900 shares of the biopharmaceutical company’s stock valued at $527,000 after buying an additional 21,900 shares in the last quarter. Finally, FMR LLC raised its position in Fate Therapeutics by 2.0% in the fourth quarter. FMR LLC now owns 4,391,885 shares of the biopharmaceutical company’s stock valued at $11,024,000 after buying an additional 84,400 shares in the last quarter. 47.08% of the stock is currently owned by institutional investors and hedge funds.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

5 Day Chart for NASDAQ:FATE

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/fate-therapeutics-inc-fate-given-new-7-00-price-target-at-bmo-capital-markets/1709219.html

Receive News & Ratings for Fate Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *